MedPath

HERBERT HURWITZ MD

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Dose Escalation Study of Pazopanib Plus TH-302

Phase 1
Completed
Conditions
Solid Tumors
Interventions
First Posted Date
2011-12-05
Last Posted Date
2017-09-01
Lead Sponsor
Herbert Hurwitz, MD
Target Recruit Count
50
Registration Number
NCT01485042
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Duke Cancer Institute, Durham, North Carolina, United States

XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib

Phase 1
Completed
Conditions
Solid Tumor
Metastatic Colorectal Cancer
Interventions
First Posted Date
2009-06-15
Last Posted Date
2016-02-03
Lead Sponsor
Herbert Hurwitz, MD
Target Recruit Count
22
Registration Number
NCT00920868
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Rocky Mountain Cancer Center, Denver, Colorado, United States

๐Ÿ‡บ๐Ÿ‡ธ

Duke Univeristy Medical Center, Durham, North Carolina, United States

Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors

Phase 1
Completed
Conditions
Solid Tumors
Interventions
Drug: CNTO 95 and avastin
First Posted Date
2009-04-24
Last Posted Date
2015-03-11
Lead Sponsor
Herbert Hurwitz, MD
Target Recruit Count
13
Registration Number
NCT00888043
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Duke University Medical Center, Durham, North Carolina, United States

BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)

Phase 1
Completed
Conditions
Solid Tumors
Interventions
First Posted Date
2008-01-04
Last Posted Date
2014-11-19
Lead Sponsor
Herbert Hurwitz, MD
Target Recruit Count
56
Registration Number
NCT00586443
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Duke University Medical Center, Durham, North Carolina, United States

Bevacizumab in Treating Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Biological: Bevacizumab (Avastin)
First Posted Date
2006-12-28
Last Posted Date
2016-07-07
Lead Sponsor
Herbert Hurwitz, MD
Target Recruit Count
27
Registration Number
NCT00416637

Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Phase 2
Completed
Conditions
Colorectal Cancer
Interventions
First Posted Date
2006-12-28
Last Posted Date
2014-09-03
Lead Sponsor
Herbert Hurwitz, MD
Target Recruit Count
50
Registration Number
NCT00416494

Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
First Posted Date
2006-01-13
Last Posted Date
2014-11-19
Lead Sponsor
Herbert Hurwitz, MD
Target Recruit Count
65
Registration Number
NCT00276575
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath